Evaluation of bacteriophage cocktail on septicaemia caused by colistin-resistant Acinetobacter baumannii in immunocompromised mice model

Patel, Shesh Raj; Pratap, Chandra Bhan; Nath, Gopal

doi:10.4103/ijmr.ijmr_2271_18

Cited by 9 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Afterall, the ability to eliminate biofilms was demonstrated in-vivo, and noted that vancomycin and PlySs2 (a bacteriophage-derived lysin) together can lower the bacterial burden in periprosthetic tissues and on implant surfaces in the well-established mouse model of prosthetic joint infection [113]. Moreover, Pater et al [114] phage cocktails have been formulated, consisting of three phages (ΦAb4, ΦAb7, and ΦAb14). Their effects were tested on immunocompromised rodents with septicemia caused by MDR A. baumannii.…”

Section: Bacteriophage Therapymentioning

confidence: 99%

See 1 more Smart Citation

Understanding the biofilm development of Acinetobacter baumannii and novel strategies to combat infection

Naseef Pathoor,

Viswanathan,

Wadhwa

et al. 2024

APMIS

View full text Add to dashboard Cite

Acinetobacter baumannii (A. baumannii) is a Gram‐negative, nonmotile, and aerobic bacillus emerged as a superbug, due to increasing the possibility of infection and accelerating rates of antimicrobial agents. It is recognized as a nosocomial pathogen due to its ability to form biofilms. These biofilms serve as a defensive barrier, increase antibiotic resistance, and make treatment more difficult. As a result, the current situation necessitates the rapid emergence of novel therapeutic approaches to ensure successful treatment outcomes. This review explores the intricate relationship between biofilm formation and antibiotic resistance in A. baumannii, emphasizing the role of key virulence factors and quorum sensing (QS) mechanisms that will lead to infections and facilitate insight into developing innovative method to control A. baumannii infections. Furthermore, the review article looks into promising approaches for preventing biofilm formation on medically important surfaces and potential therapeutic methods for eliminating preformed biofilms, which can address biofilm‐associated A. baumannii infections. Modern advances in emerging therapeutic options such as antimicrobial peptide (AMPs), nanoparticles (NPs), bacteriophage therapy, photodynamic therapy (PDT), and other biofilm inhibitors can assist readers understand the current landscape and future prospects for effectively treating A. baumannii biofilm infections.

show abstract

Section: Bacteriophage Therapymentioning

confidence: 99%

“…Moreover, Pater et al. [114] phage cocktails have been formulated, consisting of three phages (ΦAb4, ΦAb7, and ΦAb14). Their effects were tested on immunocompromised rodents with septicemia caused by MDR A .…”

Section: Emerging Therapeutic Strategiesmentioning

confidence: 99%

Understanding the biofilm development of Acinetobacter baumannii and novel strategies to combat infection

Naseef Pathoor,

Viswanathan,

Wadhwa

et al. 2024

APMIS

View full text Add to dashboard Cite

show abstract

“…At present, transcriptomic analyses of A. baumannii phages and their hosts are very scarce. Although many reports have verified the antibacterial potential of phages in vitro or in vivo, there are no data to analyze the changes in phages and bacteria globally [ 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 ]. This brings a huge workload to the clinical formulation of phage therapy or phage-antibiotic combination therapy.…”

Section: Action Of a Baumannii Phage On ...mentioning

confidence: 99%

Acinetobacter Baumannii Phages: Past, Present and Future

et al. 2023

Viruses

View full text Add to dashboard Cite

Acinetobacter baumannii (A. baumannii) is one of the most common clinical pathogens and a typical multi-drug resistant (MDR) bacterium. With the increase of drug-resistant A. baumannii infections, it is urgent to find some new treatment strategies, such as phage therapy. In this paper, we described the different drug resistances of A. baumannii and some basic properties of A. baumannii phages, analyzed the interaction between phages and their hosts, and focused on A. baumannii phage therapies. Finally, we discussed the chance and challenge of phage therapy. This paper aims to provide a more comprehensive understanding of A. baumannii phages and theoretical support for the clinical application of A. baumannii phages.

show abstract

“…There is already data in ABI suggesting the efficacy of phage therapy in animal or in vitro models [195 ▪ ,196 ▪ ,198 ▪ ,209 ▪ –211 ▪ ,212–214,215 ▪ ].…”

Section: What Are the Alternative Treatments For Acinetobacter Bauman...mentioning

confidence: 99%

How to treat severe Acinetobacter baumannii infections

Bouza,

Muñoz,

Burillo

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review To update the management of severe Acinetobacter baumannii infections (ABI), particularly those caused by multi-resistant isolates. Recent findings The in vitro activity of the various antimicrobial agents potentially helpful in treating ABI is highly variable and has progressively decreased for many of them, limiting current therapeutic options. The combination of more than one drug is still advisable in most circumstances. Ideally, two active first-line drugs should be used. Alternatively, a first-line and a second-line drug and, if this is not possible, two or more second-line drugs in combination. The emergence of new agents such as Cefiderocol, the combination of Sulbactam and Durlobactam, and the new Tetracyclines offer therapeutic options that need to be supported by clinical evidence. Summary The apparent limitations in treating infections caused by this bacterium, the rapid development of resistance, and the serious underlying situation in most cases invite the search for alternatives to antibiotic treatment, the most promising of which seems to be bacteriophage therapy.

show abstract

Evaluation of bacteriophage cocktail on septicaemia caused by colistin-resistant Acinetobacter baumannii in immunocompromised mice model

Cited by 9 publications

References 25 publications

Understanding the biofilm development of Acinetobacter baumannii and novel strategies to combat infection

Understanding the biofilm development of Acinetobacter baumannii and novel strategies to combat infection

Acinetobacter Baumannii Phages: Past, Present and Future

How to treat severe Acinetobacter baumannii infections

Contact Info

Product

Resources

About